Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584607 | 1.00 | HCAR2 (0.50) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL27944350 | 0.98 | HCAR2 (0.48) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3803618 | 0.88 | KDM4E (0.55) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3803622 | 0.88 | KDM4E (0.55) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2434127 | 0.85 | PKM (0.55) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1167211 | 0.85 | HCAR2 (0.48) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1167208 | 0.85 | HCAR2 (0.48) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2434129 | 0.85 | PKM (0.55) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16049121 | 0.85 | PKM (0.55) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20475356 | 0.83 | HCAR2 (0.47) | HCAR2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1429768-B1 | NOVEL MEDICAMENTS FOR INHALATION | BOEHRINGER INGELHEIM PHARMA (DE) | 2016-11-16 | — | — | EP | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-17 | — | — | US | claimed |
| US-6919325-B2 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-07-19 | — | — | US | claimed |
| EP-1429768-A1 | NOVEL MEDICAMENTS FOR INHALATION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-06-23 | — | — | EP | claimed |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
| WO-2003024452-A1 | NOVEL MEDICAMENTS FOR INHALATION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | claimed |
| CN-114591255-B | Pleuromutilin derivative containing 1,2, 4-triazole acrylamide side chain and preparation method and application thereof | 西安康远晟生物医药科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-116621904-A | Cinnamoyl ursodeoxycholic acid compound and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药用植物研究所 | 2023-08-22 | — | — | CN | disclosed |
| CN-116354823-A | Preparation method and application of compound | 武汉珈海智药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-114605418-A | Ibrutinib acrylamide derivative with antitumor activity and synthesis method and application thereof | 广东医科大学附属医院 | 2022-06-10 | — | — | CN | disclosed |
| CN-114591255-A | Pleuromutilin derivative containing 1,2, 4-triazole acrylamide side chain as well as preparation method and application thereof | 西安康远晟生物医药科技有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-108912011-B | Photoalignment material | 罗立克科技股份公司 | 2021-09-24 | — | — | CN | disclosed |
| US-20060069123-A1 | Substituted dipiperidine CCR2 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | disclosed |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-17 | — | — | US | disclosed |
| US-6919325-B2 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-07-19 | — | — | US | disclosed |
| US-6277502-B1 | ORGANOSILICON POLYMERS; LIQUID CRYSALS | ROLIC AG (CH) | 2001-08-21 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069123-A1 | Substituted dipiperidine CCR2 antagonists | CCR2, CCR1, CCR5 | HCAR2 77/4885HDAC3 443/4885HDAC4 2342/4885 |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | ADRB3, ADRB1, HSD3B1 | HCAR2 1873/4885HDAC3 2896/4885HDAC4 3336/4885 |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | ADRB3, ADRB1, CHRM3 | HCAR2 1526/4885HDAC3 2931/4885HDAC4 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.